Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Relying On 'Six Stars' And Other R&D Programs To Blunt Restasis Blow

Executive Summary

Allergan will spend 2018 trying to shift investor focus from the loss of Restasis patent exclusivity in the second half of the year to the company's R&D pipeline, including the late-stage "six stars" highlighted in 2017 and mid-stage programs that are moving into the spotlight.

Advertisement

Related Content

J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
Allergan Hopes To Add Bipolar Depression To Vraylar's Label
Allergan Readies Cost Cuts As Restasis Generics Approach
Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents
Could High Profile Combo Be Allergan/Novartis Answer To Late-Stage NASH Programs?
Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma
‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study
Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Allergan paying $560m for Naurex; stays quiet on rumored generics sale to Teva

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100228

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel